Lyell Immunopharma Income Statement (2020-2026) | LYEL

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
0.01M0.01M12.27M12.36M12.46M12.48M12.48M12.55M12.59M12.70M12.75M12.80M12.83M14.74M14.76M14.83M19.29M17.09M23.33M23.40M
Revenue & cost
Revenue (Quarter)
2.75M2.82M0.55M35.74M0.00M48.39M0.07M0.03M0.03M0.01M0.00M0.01M0.03M0.01M0.01M0.01M0.01M0.01M0.00M0.00M
Operating items
Research & Development (Quarter)
31.43M19.29M35.83M43.72M41.61M38.03M44.63M47.47M43.85M46.99M43.17M40.26M39.50M48.67M43.45M34.86M28.17M52.20M36.60M39.52M
Selling, General & Administrative (Quarter)
21.24M31.87M34.42M30.45M26.08M26.35M19.28M19.03M15.51M13.17M13.49M12.26M11.77M14.52M14.05M9.79M10.69M10.62M9.55M9.58M
Other Operating Expenses (Quarter)
0.76M0.80M1.12M1.17M1.25M1.21M1.29M0.57M0.29M0.64M1.09M0.98M0.73M0.51M0.12M-1.06M1.59M1.50M1.90M1.76M
Operating Expenses (Quarter)
51.92M50.36M69.13M73.00M66.44M63.17M62.62M65.93M59.06M59.52M55.58M51.54M50.54M201.16M57.37M47.15M37.27M127.65M44.26M47.34M
Operating Income (Quarter)
-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M-47.34M
EBIT (Quarter)
-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M-47.34M
Non-operating items
Interest & Investment Income (Quarter)
-0.14M-1.56M-4.98M-1.75M-1.65M2.40M3.72M1.50M1.20M1.09M-0.31M0.01M1.16M-0.47M-0.13M-0.10M0.14M0.04M-0.25M-0.15M
Other Non Operating Income (Quarter)
0.02M-0.04M0.04M-0.01M-1.07M2.93M1.10M-0.33M1.58M-0.51M1.09M-0.65M-0.04M4.29M1.31M1.18M-4.86M-15.76M17.91M0.40M
Non Operating Income (Quarter)
0.29M0.44M0.40M0.94M-3.82M6.39M4.50M5.26M6.61M6.58M-5.09M6.36M5.92M-3.39M5.17M3.28M-1.59M2.68M2.19M2.58M
Net income details
EBT (Quarter)
-60.65M-176.32M-175.37M-129.98M-188.38M-13.56M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M-102.94M
Profit After Tax (Quarter)
-48.88M-85.58M-68.14M-36.32M-71.90M-6.00M-66.96M-63.89M-49.66M-52.93M-60.67M-45.81M-43.43M-192.40M-52.20M-42.68M-38.70M-140.77M-24.40M-44.90M
Income from Continuing Operations (Quarter)
-60.65M-176.32M-175.37M-129.98M-188.38M-13.56M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M-102.94M
Consolidated Net Income (Quarter)
-60.65M-176.32M-175.37M-129.98M-188.38M-13.56M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M-102.94M
Income towards Parent Company (Quarter)
-60.65M-176.32M-175.37M-129.98M-188.38M-13.56M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M-102.94M
Net Income towards Common Stockholders (Quarter)
-60.65M-176.32M-175.37M-129.98M-188.38M-13.56M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M-102.94M
Additional items
EPS (Basic) (Quarter)
-0.01M-0.03M-14.36-10.55-15.17-1.10-6.68-7.26-5.57-24.45-5.89-10.14-9.71-42.91-8.73-7.81-5.59-8.47-4.72-4.41
EPS (Diluted) (Quarter)
-5.07-0.03M-14.36-10.55-15.17-1.10-6.68-7.26-5.57-24.45-5.89-10.14-9.71-42.91-8.73-7.81-5.59-8.47-4.72-4.41
Shares Outstanding (Quarter)
0.01M0.01M12.21M12.32M12.42M12.35M12.48M12.51M12.57M12.55M12.71M12.77M12.82M13.07M14.75M14.79M18.27M17.09M21.88M23.36M
Shares Outstanding (Diluted) (Quarter)
11.97M0.01M12.21M12.32M12.42M12.35M12.48M12.51M12.57M12.55M12.71M12.77M12.82M13.07M14.75M14.79M18.27M17.09M21.88M23.36M
EBITDA (Quarter)
-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M-47.34M
Interest Expenses (Quarter)
11.35M127.23M101.82M90.97M120.30M1.17M24.47M26.40M12.21M248.42M19.02M77.96M75.06M359.44M71.38M68.23M65.06M17.09M58.70M55.45M